Mast cells are upregulated in Hidradenitis Suppurativa Tissue, associated with epithelialized tunnels and normalised by Spleen Tyrosine Kinase Antagonism - Flora, A; Jepsen, R; Kozera, EK; Woods, JA; Cains, GD; Radzieta, M; Jensen, SO; Malone, M; Frew, JW (medRxiv, 2023)
Mast cells have traditionally been associated with allergic inflammatory responses; however they play important roles in cutaneous innate immunity and wound healing. The Hidradenitis Suppurativa tissue transcriptome is associated with alterations in innate immunity and wound healing associated pathways, however the role of Mast cells in the disease is unexplored. We demonstrate that Mast cell associated gene expression (using whole tissue RNAseq) is upregulated, and in-silico cellular deconvolution identifies activated mast cells upregulated and resting mast cells downregulated in lesional tissue. Tryptase/Chymase positive Mast cells (identified using IHC) localize adjacent to epithelialised tunnels, fibrotic regions of the dermis and at perivascular sites associated with Neutrophil Extracellular Trap formation and TNF-alpha production.Treatment with Spleen Tyrosine Kinase antagonist (Fostamatinib) reduces the expression of mast cell associated gene transcripts, associated biochemical pathways, and number of tryptase/chymase positive mast cells in lesional hidradenitis suppurativa tissue.This data indicates that although Mast cells are not the most abundant cell type in Hidradenitis Suppurativa tissue, the dysregulation of mast cells is associated with B cell/plasma cell inflammation, inflammatory epithelialized tunnels and epithelial budding. This provides an explanation as to the mixed inflammatory activation signature seen in HS, the correlation with dysregulated wound healing and potential pathways involved in the development of epithelialized tunnels.Competing Interest StatementJWF has conducted advisory work for Janssen, Boehringer-Ingelheim, Pfizer, Kyowa Kirin, LEO Pharma, Regeneron, Chemocentryx, Abbvie, Azora, Novartis and UCB, participated in trials for Pfizer, UCB, Boehringer-Ingelheim, Eli Lilly, CSL, Azora and received research support from Ortho Dermatologics, Sun Pharma, LEO Pharma, UCB and La Roche Posay.Clinical TrialNCT05040698Funding StatementNilAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the human research ethics committee of Sydney South West Area Health Service (Sydney Australia).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesBaseline RNA sequencing Data is publicly available using SRA Bioproject ID: PRJNA912704 Nanostring Data is publicly available using GEO Accession Number GSE220454